Bret Poat
Overview
Explore the profile of Bret Poat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandra P, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, et al.
Virol J
. 2024 Nov;
21(1):274.
PMID: 39487495
No abstract available.
2.
Chandra P, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, et al.
PLoS One
. 2014 Sep;
9(9):e108616.
PMID: 25265476
Purpose: Chronic Hepatitis C Virus (HCV)-infected patients with liver cirrhosis (LC) respond poorly to interferon-alpha (IFN-α) and ribavirin (RBV) combination therapy, but the reason for this is unclear. We previously...
3.
Gunduz F, Aboulnasr F, Chandra P, Hazari S, Poat B, Baker D, et al.
Virol J
. 2012 Aug;
9:143.
PMID: 22863531
Background: Hepatic steatosis is recognized as a major risk factor for liver disease progression and impaired response to interferon based therapy in chronic hepatitis C (CHC) patients. The mechanism of...
4.
Datta S, Hazari S, Chandra P, Samara M, Poat B, Gunduz F, et al.
Virol J
. 2011 Jul;
8:351.
PMID: 21756311
The mechanisms underlying the Hepatitis C virus (HCV) resistance to interferon alpha (IFN-α) are not fully understood. We used IFN-α resistant HCV replicon cell lines and an infectious HCV cell...
5.
Hepatocellular carcinoma xenograft supports HCV replication: a mouse model for evaluating antivirals
Hazari S, Hefler H, Chandra P, Poat B, Gunduz F, Ooms T, et al.
World J Gastroenterol
. 2011 Jan;
17(3):300-12.
PMID: 21253388
Aim: To develop a hepatocellular carcinoma (HCC) xenograft model for studying hepatitis C virus (HCV) replication in a mice, and antiviral treatment. Methods: We developed a stable S3-green fluorescence protein...
6.
Poat B, Hazari S, Chandra P, Gunduz F, Balart L, Alvarez X, et al.
PLoS One
. 2010 Oct;
5(9).
PMID: 20949125
Background: We have developed multiple stable cell lines containing subgenomic HCV RNA that are resistant to treatment with interferon alpha (IFN-α. Characterization of these IFN-α resistant replicon cells showed defects...
7.
Poat B, Hazari S, Chandra P, Gunduz F, Alvarez X, Balart L, et al.
Virol J
. 2010 Oct;
7:265.
PMID: 20939906
Interferon alpha (IFN-α) binds to a cell surface receptor that activates the Jak-Stat signaling pathway. A critical component of this pathway is the translocation of interferon stimulated gene factor 3...
8.
Chandra P, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, et al.
Virol J
. 2010 Jun;
7:118.
PMID: 20529250
Background: Hepatitis C virus (HCV) infection is a major public health problem with more than 170 million cases of chronic infections worldwide. There is no protective vaccine currently available for...
9.
Hazari S, Chandra P, Poat B, Datta S, Garry R, Foster T, et al.
Virol J
. 2010 Feb;
7:36.
PMID: 20149251
Background: The sustained virological response to interferon-alpha (IFN-alpha) in individuals infected with hepatitis C virus (HCV) genotype 1 is only 50%, but is about 80% in patients infected with genotype...